When Danaher Corporation announced on February 17 that it would acquire Masimo Corporation for $9.9 billion in cash, the deal did more than make Masimo shareholders substantially richer. It sent an unmistakable signal to every corner of the medical device industry: the era of patient monitoring as a commodity business is over, and the companies that own the most sophisticated real-time health data platforms are about to become the most valuable assets in healthcare.
The Deal at a Glance
Danaher is paying $180 per share in cash for all outstanding Masimo common stock, a premium of nearly 40% over Masimo's closing price on February 13. The total enterprise value, including assumed debt and net of acquired cash, comes to approximately $9.9 billion. It is the largest medtech acquisition announced globally since 2023 and one of the biggest healthcare deals of any kind so far in 2026.
The transaction values Masimo at roughly 18 times its estimated 2027 EBITDA before synergies, or approximately 15 times after Danaher factors in $125 million in expected annual cost savings and an additional $50 million in revenue synergies by the fifth full year of ownership. Under Danaher's stewardship, Masimo is projected to generate more than $530 million in EBITDA by 2027.
Why Masimo, and Why Now
Masimo is not a household name, but within hospital walls it is a standard-bearer. The company's Signal Extraction Technology, or SET, is widely regarded as the gold standard in pulse oximetry, the measurement of oxygen saturation in a patient's blood. Masimo's devices are used in virtually every major hospital system in the United States and increasingly in outpatient and home-care settings.
The company generated $2.18 billion in trailing twelve-month revenue before the deal was announced, with a product portfolio that extends well beyond pulse oximeters into brain function monitoring, capnography, hemoglobin measurement, and a growing suite of wireless, wearable sensors designed for continuous monitoring outside traditional hospital settings.
It is that last category, remote and continuous monitoring, that makes Masimo so strategically valuable. The hospital-at-home movement, which accelerated dramatically during the pandemic and has since become a permanent feature of the American healthcare landscape, depends on exactly the kind of real-time, high-fidelity patient data that Masimo's technology provides. Hospitals are under relentless pressure to reduce readmission rates, shorten lengths of stay, and manage chronic conditions at lower cost. All of those imperatives point toward more monitoring, not less, and toward monitoring that happens outside the four walls of an acute care facility.
Danaher's Broader Strategy
For Danaher, the acquisition is the latest step in a transformation that has been unfolding for more than a decade. The company, which began as an industrial conglomerate, has systematically divested its legacy businesses and rebuilt itself as a life sciences and diagnostics powerhouse. The 2023 spinoff of its environmental and applied solutions segment into a separate company, Veralto, completed the pivot. Today, Danaher's portfolio includes Beckman Coulter (clinical diagnostics), Cepheid (molecular diagnostics), Cytiva (bioprocessing), and Leica Microsystems (scientific instruments), among others.
Adding Masimo gives Danaher a dominant position in patient monitoring, a market that consulting firm Grand View Research estimates will be worth $71 billion globally by 2030. More importantly, it gives Danaher a continuous data stream from millions of patients, data that can be integrated with its existing diagnostics platforms to create a more comprehensive picture of patient health than any single device or test can provide on its own.
What the Premium Tells the Market
A 40% premium in a market where medtech valuations have compressed significantly over the past two years is a statement of conviction. Danaher is not buying Masimo because it was cheap. The company is buying Masimo because it believes the patient-monitoring market is on the verge of a structural expansion that will make today's prices look like a bargain in retrospect.
The math behind that conviction is straightforward. The United States has 55 million adults over the age of 65 today. By 2030, that number will exceed 73 million. The prevalence of chronic conditions, diabetes, heart failure, COPD, hypertension, rises exponentially with age. Managing those conditions in a hospital costs roughly $3,000 per day. Managing them at home with continuous remote monitoring costs a fraction of that. The economics are so compelling that the Centers for Medicare and Medicaid Services has been steadily expanding reimbursement for remote patient monitoring services, creating a regulatory tailwind that shows no sign of reversing.
The M&A Implications
If history is any guide, deals of this size and strategic clarity tend to catalyze additional transactions. The medtech M&A market has been relatively quiet over the past eighteen months, constrained by high interest rates, regulatory uncertainty, and the hangover from a wave of deals in 2021 and 2022 that produced mixed results. Danaher's willingness to pay a substantial premium for Masimo suggests that at least some acquirers believe the window of compressed valuations is closing.
Analysts at Morgan Stanley noted in a report published the day after the announcement that several other patient-monitoring and remote-care companies could become targets, including ICU Medical, Insulet, and ResMed. The logic is simple: if Danaher believes patient monitoring is worth paying up for, other large healthcare companies, Medtronic, Abbott, GE HealthCare, Johnson & Johnson's MedTech division, may reach the same conclusion before valuations rise further.
What It Means for Investors
The Danaher-Masimo deal offers three lessons for investors watching the healthcare sector. First, medical devices are no longer a sleepy corner of the market. The convergence of aging demographics, remote-care technology, and AI-driven diagnostics is creating growth opportunities that rival anything in software or pharmaceuticals. Second, companies with proprietary data platforms and regulatory moats, the Masimos, the Dexcoms, the Abbotts, command premiums that are likely to expand, not contract, as the hospital-at-home model scales. Third, the return of large-scale M&A in medtech could provide a valuation floor for the entire sector, many of whose stocks have underperformed the broader market over the past year.
The transaction is expected to close in the second half of 2026, subject to regulatory approvals and a vote by Masimo shareholders. For the rest of the medtech industry, the clock started ticking the moment the press release hit the wire.
